157 related articles for article (PubMed ID: 38283482)
1. Sodium-Glucose Cotransporter-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a Type 2 Diabetic Patient.
Haddadin R; Aboujamra D; Iraninezhad H
Cureus; 2023 Dec; 15(12):e51184. PubMed ID: 38283482
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice.
Patoulias D; Manafis A; Mitas C; Avranas K; Lales G; Zografou I; Sambanis C; Karagiannis A
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):139-146. PubMed ID: 29412120
[TBL] [Abstract][Full Text] [Related]
3. "Normal but Catastrophic" Euglycemic Diabetic Ketoacidosis Precipitated by Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.
Sarno MJF; Hernandez DPF; Matulac MO
Cureus; 2023 Nov; 15(11):e49236. PubMed ID: 38143642
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus.
Chauhan S; Manov A; Dhillon GS; Shah P
Cureus; 2023 Jan; 15(1):e33892. PubMed ID: 36819400
[TBL] [Abstract][Full Text] [Related]
5. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
He Z; Lam K; Zhao W; Yang S; Li Y; Mo J; Gao S; Liang D; Qiu K; Huang M; Wu J
Acta Diabetol; 2023 Mar; 60(3):401-411. PubMed ID: 36576563
[TBL] [Abstract][Full Text] [Related]
6. The Significance of Precise Diabetes Diagnosis: A Case of Euglycemic Diabetic Ketoacidosis Induced by the Introduction of Empagliflozin with Simultaneous Reduction of Insulin Dosage.
Bińczyk W; Dróżdż O; Siudek B; Głuszczyk AM; Plizga JI; Grajnert FJ
Eur J Case Rep Intern Med; 2024; 11(6):004567. PubMed ID: 38846667
[TBL] [Abstract][Full Text] [Related]
7. Delayed euDKA Associated With Dapagliflozin After Pancreatitis.
Wu G; Wu S; Tang J; Wu H
Clin Ther; 2023 Jul; 45(7):e167-e170. PubMed ID: 37248092
[TBL] [Abstract][Full Text] [Related]
8. Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature.
Mistry S; Eschler DC
AACE Clin Case Rep; 2021; 7(1):17-19. PubMed ID: 33851013
[TBL] [Abstract][Full Text] [Related]
9. SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review.
Mahfooz RS; Khan MK; Al Hennawi H; Khedr A
Cureus; 2022 Jun; 14(6):e26267. PubMed ID: 35911365
[TBL] [Abstract][Full Text] [Related]
10. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
Dull RB; Spangler ML; Knezevich EL; Lau BM
J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
[TBL] [Abstract][Full Text] [Related]
11. Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy.
Pace DJ; Dukleska K; Phillips S; Gleason V; Yeo CJ
J Pancreat Cancer; 2018; 4(1):95-99. PubMed ID: 30631862
[No Abstract] [Full Text] [Related]
12. "The Bitter Truth of Sugar"-Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series.
Shah M; Pathrose E; Bhagwat NM; Chandy D
Indian J Crit Care Med; 2022 Jan; 26(1):123-126. PubMed ID: 35110855
[TBL] [Abstract][Full Text] [Related]
13. Post-Operative Euglycemic Diabetic Ketoacidosis in a Patient With SGLT-2 Inhibitor Use and Recent Sleeve Gastrectomy.
Smith A; Holtrop J; Sadoun M
Cureus; 2021 Apr; 13(4):e14297. PubMed ID: 33968511
[TBL] [Abstract][Full Text] [Related]
14. Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors.
Vitale RJ; Valtis YK; McDonnell ME; Palermo NE; Fisher NDL
AACE Clin Case Rep; 2021; 7(1):10-13. PubMed ID: 33521255
[TBL] [Abstract][Full Text] [Related]
15. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.
Sampani E; Sarafidis P; Dimitriadis C; Kasimatis E; Daikidou D; Bantis K; Papanikolaou A; Papagianni A
BMC Nephrol; 2020 Jul; 21(1):276. PubMed ID: 32669085
[TBL] [Abstract][Full Text] [Related]
16. Severe euglycemic diabetic ketoacidosis secondary to sodium-glucose co-transporter 2 inhibitor: case report and literature review.
El Ess MS; ElRishi MA
Ann Med Surg (Lond); 2023 May; 85(5):2097-2101. PubMed ID: 37228937
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysiology and contributing factors.
Lin YH
J Formos Med Assoc; 2018 Sep; 117(9):849-854. PubMed ID: 29477576
[TBL] [Abstract][Full Text] [Related]
18. Hypertriglyceridemia-Induced Acute Pancreatitis, Euglycemic Diabetic Ketoacidosis and COVID-19 Infection in a Patient With Type 2 Diabetes Taking a Sodium-Glucose Cotransporter 2 Inhibitor.
Acevedo-Mendez BA; Ye Y; Hajizadeh N; Myers A
Cureus; 2021 Nov; 13(11):e19828. PubMed ID: 34853772
[TBL] [Abstract][Full Text] [Related]
19. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
Diaz-Ramos A; Eilbert W; Marquez D
Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Presenting with Acute Pancreatitis.
Badwal K; Tariq T; Peirce D
Case Rep Endocrinol; 2018; 2018():6450563. PubMed ID: 30159178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
